Year: 2020
Language: English
Author(s): World Federation of Hemophilia
In this session from the WFH 2020 Virtual Summit, Deniece Chevannes, Jayson Stoffman, Niamh O’Connell, John Sarmenta and Luisa Durante discuss the WFH twinning program.
The Twinning Program creates short-term collaborative partnerships between medical professionals as well as patient and youth leaders in developing and developed countries for a period of two to four years. This session will celebrate the award-winning accomplishments of Hemophilia Treatment Care Twins of the year and the Hemophilia Organization Twins of the year.
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.
Listen to this 90-minute webinar presented on March 7, 2025, to learn about women and girls with bleeding disorders (WGBD).
The Report on Annual Global Survey (AGS) includes demographic and treatment data, providing a global snapshot of people with hemophilia,
This patient handbook contains basic information about the inheritance, diagnosis, symptoms and management of fibrinogen disorders, including afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia
Publishing in Haemophilia—the official journal of the WFH—presents both opportunities and challenges for researchers and practitioners in the field. While
The WFH Shared Decision Making (SDM) Workbook is for people with hemophilia A or B and their healthcare team. It
The World Bleeding Disorders Registry (WBDR) 2023 Data Report provides aggregate data on more than 14,000 people with hemophilia &
